3171-46-8

Basic information

• Product Name: 3,5-Dimethyl-1,2-phenylenediamine
• Synonyms: 3,5-Dimethyl-1,2-phenylenediamine;3,5-DIMETHYLBENZENE-1,2-DIAMINE;m-Xylene-4,5-diamine;(2-amino-3,5-dimethylphenyl)amine(SALTDATA: FREE);1,2-Diamino-3,5-dimethylbenzene;(2-amino-4,6-dimethyl-phenyl)amine
• CAS NO: 3171-46-8
• Molecular Formula: C₈H₁₂N₂
• Molecular Weight: 136.2
• EINECS: 221-635-1
• Product Categories: Building Blocks;Chemical Synthesis;Nitrogen Compounds;Organic Building Blocks;Polyamines
• Mol File: 3171-46-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 73-78℃
• Boiling Point: 279.6°C at 760 mmHg
• Flash Point: 144.9°C
• Appearance: /
• Density: 1.076g/cm³
• Vapor Pressure: 0.00399mmHg at 25°C
• Refractive Index: 1.618
• Storage Temp.: 2-8°C
• PKA: 4.45±0.10(Predicted)
• CAS DataBase Reference: 3,5-Dimethyl-1,2-phenylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-Dimethyl-1,2-phenylenediamine(3171-46-8)
• EPA Substance Registry System: 3,5-Dimethyl-1,2-phenylenediamine(3171-46-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 3171-46-8(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 3171-46-8 differently. You can refer to the following data:
1. 3,5-Dimethylbenzene-1,2-diamine is a useful reagent for the synthesis of benzimidazoles and benzimidazole conjugates.
2. 1,2-Diamino-3,5-dimethylbenzene can be used as a starting material to synthesize: Tetramethyl quinoxaline derivatives by reacting with 1,2-dicarbonyl compounds. 5,7-Dimethyl-1H-benzotriazole by reacting with tert-butyl nitrite. Dimethyl-1H-benzimidazole by reacting with dimethylformamide (DMF).

InChI:InChI=1/C8H12N2/c1-5-3-7(9)8(10)4-6(5)2/h3-4H,9-10H2,1-2H3

Upstream product

• 7647-01-0 hydrogenchloride 
• 6417-44-3 2-(2,4-dimethyl-phenylazo)-4,6-dimethyl-aniline 
• 89209-03-0 4,6-dimethyl-2,1,3-benzothiadiazole 
• 1635-84-3 2,4-Dimethyl-6-nitroanilin 
• 65151-56-6 3,5-dimethyl-1,2-dinitrobenzene 
• 99-12-7 5-nitro-m-xylene 
• 95-68-1 2,4-Xylidine 
• 90434-19-8 dibromo-m-xylene 
• 2050-43-3 N-(2,4-dimethylphenyl)acetamide 
• 90111-03-8 1,3-dibromo-2,4-dimethyl-5,6-dinitro-benzene 

Downstream Products

• 4602-06-6 4,6-Dimethyl-2-phenyl-2,3-dihydro-1H-1,3,2-benzodiazaphosphol-2-oxid 
• 4600-23-1 4,6-Dimethyl-2-phenyl-2,3-dihydro-1H-1,3,2-benzodiaza-phosphol-2-sulfid 
• 111337-08-7 2,4-Bis-(4-chloro-phenyl)-2,6,8-trimethyl-2,3-dihydro-1H-benzo[b][1,4]diazepine 
• 73590-92-8 4,6-dimethylbenzimidazole-2-thione 
• 111337-06-5 2,6,8-trimethyl-2,4-diphenyl-2,3-dihydro-1H-1,5-benzodiazepine 
• 111337-07-6 2,4-Bis-(4-ethoxy-phenyl)-2,6,8-trimethyl-2,3-dihydro-1H-benzo[b][1,4]diazepine 
• 111337-09-8 2,6,8-Trimethyl-2,4-bis-(4-nitro-phenyl)-2,3-dihydro-1H-benzo[b][1,4]diazepine 
• 60190-75-2 C₄₄H₃₈N₂P₂ 
• 60190-73-0 C₂₆H₂₅N₂P 
• 69557-54-6 4,6-dimethylbenzimidazole 
• 102308-68-9 4,6-dimethyl-1H-benzimidazol-2(3H)-one 

Relevant articles and documents

Synthetic method of 2-n-propyl-4-methylbenzimidazole-6-carboxylic acid

The invention relates to a synthetic method of 2-n-propyl-4-methylbenzimidazole-6-carboxylic acid. The synthetic method comprises the following steps: through nitric acid/concentrated sulfuric acid nitrification reaction of 3,5-dimethylnitrobenzene, generating an intermediate product II, namely 3,5-dimethyl-1,2-dinitrobenzene; performing Pd/C catalytic hydrogenation reaction on the intermediate product II in an ethanol solution to obtain an intermediate product III, namely 3,5-dimethyl-1,2-phenylenediamine; enabling the intermediate product III to react with N-butyric acid in a polyphosphoric acid solution to obtain an intermediate product IV, namely 2-n-propyl-4,6-dimethylbenzimidazole; performing cobalt salt air liquid-phase oxidation reaction on the intermediate product IV in an acetic acid solution to obtain a product V, namely the 2-n-propyl-4-methylbenzimidazole-6-carboxylic acid. The synthetic method provided by the invention has the benefits that the operation is simple, raw materials are easy to obtain, a used solvent can be recycled, the product content can reach 95 percent or above, the yield is up to 73.2 percent, the pollution is less, and the suitability for industrial production is realized.

First demonstration of positive allosteric-like modulation at the human wild type translocator protein (TSPO)

We show that changing the number and position of nitrogen atoms in the heteroatomic core of a pyrazolopyrimidine acetamide is sufficient to induce complex binding to wild type human TSPO. Only compounds with this complex binding profile lacked intrinsic effect on glioblastoma proliferation but positively modulated the antiproliferative effects of a synthetic TSPO ligand. To the best of our knowledge this is the first demonstration of allosteric-like interaction at the wild type human TSPO.

BICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula (I): (where variables A1, A2, B, J, K, m, n, R4, R5a, R5b and R5c are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.